<DOC>
	<DOCNO>NCT02127593</DOCNO>
	<brief_summary>The purpose study establish bioequivalence hormone norgestimate , norelgestromin , ethinyl estradiol norgestimate/ethinyl estradiol ( NGM/EE ) tablet , formulate wet process compare hormone NGM/EE tablet , formulate dry process , healthy woman .</brief_summary>
	<brief_title>A Bioequivalence Study Norgestimate /Ethinyl Estradiol ( NGM/EE ) Tablets Manufactured 2 Different Facilities</brief_title>
	<detailed_description>This Phase 1 , single-dose , open-label ( medical research study participant researcher tell treatment participant receive , `` unblinded '' ) , randomize ( study medication assign chance ) , single-center 2-way crossover ( method use switch participant one study group another clinical trial ) study healthy woman . The study consist 3 part : Screening phase , Treatment phase end-of-study withdrawal . Treatment period separate wash period least 10 day . The duration participation study individual participant approximately 7 week . All participant randomly assign 1:1 ratio 1 2 possible treatment sequence receive follow treatment : 1 oral tablet formulate wet process dry process , whereas tablet contains norgestimate 250 microgram ( mcg ) ethinyl estradiol 35 mcg . The primary endpoint study assessment pharmacokinetic parameter . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Norgestimate</mesh_term>
	<mesh_term>Norgestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Participants must either surgically sterile childbearing potential practicing effective nonhormonal method birth control ( example , copper intrauterine device , doublebarrier method , male partner sterilization ) entry throughout study If woman childbearing potential , must negative serum betahuman chorionic gonadotropin ( hCG ) pregnancy test screening ; negative urine pregnancy test Day 1 treatment period Participants must agree donate egg ( ovum , oocytes ) purpose assist reproduction study 3 month last dose Body mass index ( BMI : weight [ kilogram { kg } ] /height^2 [ meter { } ] ^2 ) 18.5 30 kg/m^2 ( inclusive ) , body weight less 50 kilogram ( kg ) high 90 kg ( 198 pound ) Participant must nonsmoker Participants levonorgestrel implant ( example , Norplant ) place remove within 30 day admission study site Contraindications combine hormonal contraceptive Participants receive medroxyprogesterone injection ( example , Depo Provera ) within 6 month admission study Use hormonal contraceptive within 30 day admission study site Participants abnormal papanicolaou ( Pap ) smear CytoRich test</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Norgestimate</keyword>
	<keyword>Ethinyl estradiol</keyword>
	<keyword>Norgestrel</keyword>
	<keyword>Norelgestromin</keyword>
	<keyword>Ortho cyclen</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Healthy Women</keyword>
</DOC>